US Stock MarketDetailed Quotes

AMLX Amylyx Pharmaceuticals

Watchlist
  • 1.930
  • +0.120+6.63%
Close May 1 16:00 ET
  • 1.929
  • -0.001-0.04%
Post 17:36 ET
131.25MMarket Cap2.76P/E (TTM)

About Amylyx Pharmaceuticals Company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees384
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com

Company Executives

  • Name
  • Position
  • Salary
  • Justin Klee
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Joshua Cohen
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Dr. Camille L. Bedrosian,M.D.
  • Chief Medical Officer
  • 2.37M
  • Gina M. Mazzariello
  • Chief Legal Officer and General Counsel
  • 3.01M
  • James M. Frates
  • Chief Financial Officer and Principal Accounting Officer
  • 3.51M
  • Dr. George Mclean Milne, Jr,PhD
  • Chairman of the Board
  • 385.07K
  • Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
  • Director
  • --
  • Karen Firestone
  • Independent Director
  • 681.15K
  • Paul Fonteyne, M.S.
  • Independent Director
  • 342.12K
  • Daphne E. Quimi
  • Independent Director
  • 348.59K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg